CL2016002196A1 - Receptor antigénico quimérico - Google Patents

Receptor antigénico quimérico

Info

Publication number
CL2016002196A1
CL2016002196A1 CL2016002196A CL2016002196A CL2016002196A1 CL 2016002196 A1 CL2016002196 A1 CL 2016002196A1 CL 2016002196 A CL2016002196 A CL 2016002196A CL 2016002196 A CL2016002196 A CL 2016002196A CL 2016002196 A1 CL2016002196 A1 CL 2016002196A1
Authority
CL
Chile
Prior art keywords
antigenic receptor
chimeric antigenic
chimeric
receptor
antigenic
Prior art date
Application number
CL2016002196A
Other languages
English (en)
Inventor
Martin Pulé
John Anderson
Simon Thomas
Original Assignee
Ucl Business Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Plc filed Critical Ucl Business Plc
Publication of CL2016002196A1 publication Critical patent/CL2016002196A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464469—Tumor associated carbohydrates
    • A61K39/464471—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
CL2016002196A 2014-03-06 2016-09-01 Receptor antigénico quimérico CL2016002196A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201403972A GB201403972D0 (en) 2014-03-06 2014-03-06 Chimeric antigen receptor

Publications (1)

Publication Number Publication Date
CL2016002196A1 true CL2016002196A1 (es) 2018-02-16

Family

ID=50554626

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002196A CL2016002196A1 (es) 2014-03-06 2016-09-01 Receptor antigénico quimérico

Country Status (20)

Country Link
US (3) US10975162B2 (es)
EP (4) EP3553091A1 (es)
JP (1) JP6422134B2 (es)
KR (1) KR101965040B1 (es)
CN (1) CN106536563B (es)
AU (1) AU2015225950B2 (es)
CA (1) CA2941159C (es)
CL (1) CL2016002196A1 (es)
DK (1) DK3114147T3 (es)
ES (1) ES2673123T3 (es)
GB (1) GB201403972D0 (es)
HU (1) HUE038625T2 (es)
MX (1) MX360707B (es)
NZ (1) NZ723471A (es)
PL (1) PL3114147T3 (es)
PT (1) PT3114147T (es)
RU (1) RU2685479C2 (es)
SG (1) SG11201606790XA (es)
TR (1) TR201807939T4 (es)
WO (1) WO2015132604A1 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
US11885806B2 (en) 2014-03-05 2024-01-30 Autolus Limited Method for depleting malignant T-cells

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
EP3184548A1 (en) 2015-12-23 2017-06-28 Miltenyi Biotec GmbH Chimeric antigen receptor with cytokine receptor activating or blocking domain
CA3026778A1 (en) 2016-06-07 2017-12-14 Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft Chimeric antigen receptor and car-t cells that bind bcma
WO2018064626A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Adaptive chimeric antigen receptor t-cell design
AU2018243571B2 (en) * 2017-03-31 2024-03-07 The Board Of Trustees Of The Leland Standford Junior University Methods of treating T cell exhaustion by inhibiting or modulating T cell receptor signaling
CN107365798B (zh) * 2017-07-13 2020-07-14 山东省齐鲁细胞治疗工程技术有限公司 一种携带iCasp9自杀基因的CD19-CAR-T细胞及其应用
JP2020530993A (ja) * 2017-08-02 2020-11-05 オートラス リミテッド キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞
IT201800003464A1 (it) * 2018-03-13 2019-09-13 Ospedale Pediatrico Bambino Gesu Cellule T CAR-CD30 per il trattamento di tumori CD30+
WO2019243817A1 (en) 2018-06-19 2019-12-26 Autolus Limited Cell
US20210322473A1 (en) * 2018-07-18 2021-10-21 The General Hospital Corporation Modified t cells and methods of their use
CN108864307A (zh) * 2018-07-23 2018-11-23 北京多赢时代科技有限公司 信号肽优化靶向cd19的嵌合抗原受体、表达该嵌合抗原受体的t细胞及制备方法和应用
CN108948211B (zh) * 2018-07-24 2021-08-20 北京美康基免生物科技有限公司 一种基于靶向gd2的嵌合抗原受体及其应用
GB201812474D0 (en) 2018-07-31 2018-09-12 Autolus Ltd Nucleic acid construct
CN109136244A (zh) * 2018-08-31 2019-01-04 河北璋达生物科技有限公司 一种可诱导凋亡的携带检测标签的cd20嵌合抗原受体t淋巴细胞及其应用
CN109096405B (zh) * 2018-09-20 2021-07-09 杭州普略生物科技有限公司 以gd2为靶点的嵌合抗原受体及药物组合物
WO2020072705A1 (en) * 2018-10-03 2020-04-09 Nepenthe Biosciences, Llc Anti-cd79 antibodies and their uses
EP3919515A4 (en) * 2019-01-29 2022-11-23 Shanghai Jiao Tong University CHIMERA ANTIGEN RECEPTOR AND THEIR USE
WO2020163682A1 (en) * 2019-02-07 2020-08-13 Board Of Regents, The University Of Texas System Glucuronoxylomannan (gxm) receptor chimeric antigen receptors and use thereof
GB201903237D0 (en) 2019-03-08 2019-04-24 Autolus Ltd Method
EP3934666A1 (en) 2019-03-08 2022-01-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
TW202106704A (zh) * 2019-04-26 2021-02-16 美商艾洛基因醫療公司 抗利妥昔單抗嵌合抗原受體及其用途
WO2021020564A1 (ja) * 2019-08-01 2021-02-04 国立大学法人三重大学 Ｇｄ２結合性分子
EP4132965A2 (en) * 2020-04-06 2023-02-15 Lung Biotechnology PBC Modular synthetic receptors and methods of use
GB202007044D0 (en) 2020-05-13 2020-06-24 Autolus Ltd Method
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
GB202115329D0 (en) 2021-10-25 2021-12-08 Autolus Ltd Chimeric cytokine receptor
WO2023139360A1 (en) 2022-01-19 2023-07-27 Autolus Limited Nucleic acid construct
WO2023180511A1 (en) * 2022-03-25 2023-09-28 F. Hoffmann-La Roche Ag Improved chimeric receptors
WO2023205646A2 (en) * 2022-04-18 2023-10-26 Wisconsin Alumni Research Foundation Combinational immunotherapies using car-m, car-nk, car-eos, and car-n cells
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
CN117024605B (zh) * 2023-08-15 2024-01-09 北京市眼科研究所 嵌合抗原受体、表达嵌合抗原受体的小胶质细胞及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001023573A1 (fr) * 1999-09-30 2001-04-05 Kyowa Hakko Kogyo Co., Ltd. Anticorps transplantes a domaine de determination de complementation de type humain, dresse contre le ganglioside gd2, et derive de cet anticorps
PL211180B1 (pl) 2002-12-17 2012-04-30 Merck Patent Gmbh Białko fuzyjne typu przeciwciało-IL2, wektor zawierający sekwencję kwasów nukleinowych kodujących takie białko, kompozycja farmaceutyczna zawierająca takie białko fuzyjne oraz jego zastosowania do wytwarzania leków
FR2906808B1 (fr) 2006-10-10 2012-10-05 Univ Nantes Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers
EP2582722A4 (en) * 2010-06-19 2013-12-18 Sloan Kettering Inst Cancer ANTIBODIES AGAINST GD2
EP2614143B1 (en) * 2010-09-08 2018-11-07 Baylor College Of Medicine Immunotherapy of non-small lung cancer using genetically engineered gd2-specific t cells
PT3214091T (pt) 2010-12-09 2019-01-11 Univ Pennsylvania Utilização de células t modificadas por recetor de antigénio quimérico para tratar o cancro
WO2013040371A2 (en) * 2011-09-16 2013-03-21 Baylor College Of Medicine Targeting the tumor microenvironment using manipulated nkt cells
EA201490636A1 (ru) * 2011-09-16 2014-08-29 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Сконструированные с помощью рнк t-клетки для лечения злокачественных новообразований
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
CN103145849B (zh) * 2013-02-18 2014-06-11 冯振卿 嵌合抗原受体及其用途
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
RU2717984C2 (ru) 2013-11-21 2020-03-27 ЮСиЭл БИЗНЕС ЛТД Клетка
CN112094353A (zh) 2014-03-05 2020-12-18 奥托路斯有限公司 具有针对T细胞受体beta恒定区的抗原结合域的嵌合抗原受体(CAR)
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
MA41613A (fr) 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
GB201504840D0 (en) 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11885806B2 (en) 2014-03-05 2024-01-30 Autolus Limited Method for depleting malignant T-cells
US11885807B2 (en) 2014-03-05 2024-01-30 Autolus Limited Method for depleting malignant T-cells
US11982672B2 (en) 2014-03-05 2024-05-14 Autolus Limited Methods
US11982673B2 (en) 2014-03-05 2024-05-14 Autolus Limited Methods
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells

Also Published As

Publication number Publication date
US10975162B2 (en) 2021-04-13
RU2016138422A (ru) 2018-04-06
US20170066838A1 (en) 2017-03-09
US20240301088A1 (en) 2024-09-12
NZ723471A (en) 2020-06-26
EP3241851A1 (en) 2017-11-08
KR101965040B1 (ko) 2019-04-02
EP3553091A1 (en) 2019-10-16
EP3114147A1 (en) 2017-01-11
HUE038625T2 (hu) 2018-10-29
RU2685479C2 (ru) 2019-04-18
KR20160130451A (ko) 2016-11-11
GB201403972D0 (en) 2014-04-23
PT3114147T (pt) 2018-06-20
CA2941159C (en) 2020-07-28
ES2673123T3 (es) 2018-06-19
EP3741778A1 (en) 2020-11-25
PL3114147T3 (pl) 2018-10-31
EP3114147B1 (en) 2018-04-18
MX2016010643A (es) 2017-04-06
RU2016138422A3 (es) 2018-04-25
CN106536563A (zh) 2017-03-22
SG11201606790XA (en) 2016-09-29
JP2017508466A (ja) 2017-03-30
AU2015225950A1 (en) 2016-09-08
TR201807939T4 (tr) 2018-06-21
JP6422134B2 (ja) 2018-11-14
DK3114147T3 (en) 2018-07-30
US11879016B2 (en) 2024-01-23
BR112016020518A2 (pt) 2018-01-23
US20210403596A1 (en) 2021-12-30
MX360707B (es) 2018-11-14
CA2941159A1 (en) 2015-09-11
WO2015132604A1 (en) 2015-09-11
CN106536563B (zh) 2020-02-07
AU2015225950B2 (en) 2019-02-14

Similar Documents

Publication Publication Date Title
CL2016002196A1 (es) Receptor antigénico quimérico
IL250536A0 (en) Chimeric antigen receptors
IL254254A0 (en) chimeric antigen receptor
IL251030B (en) Chimeric antigen receptors
DK3294764T3 (da) Kimæriske antigenreceptor sammensætninger
GB201503742D0 (en) Chimeric antigen receptor
PL3230310T3 (pl) Chimeryczne receptory antygenowe anty-cd70
DK3164088T3 (da) Forbedret aterektomiindretning
BR112016027567A2 (pt) Dosador
DK2988086T3 (da) Varmeapparat
DK3126521T3 (da) HNF4G-RSPO2-fusionsgen
GB201519900D0 (en) Chimeric antigen receptor
FI20150335A (fi) Lämmityslaite
GB201409761D0 (en) Chimeric antigen receptor
TH1401005100B (th) พนักพิงหลัง
GB201403481D0 (en) Chimeric antigen receptor
ES1109982Y (es) Reposacabezas orejero
FI10485U1 (fi) Kiuas
ES1121055Y (es) Calentador de potitos
UA30137S (uk) Підлокітник
FI10914U1 (fi) Käsituki
UA29701S (uk) Підлокітник
UA29702S (uk) Підлокітник
ES1114184Y (es) Estribera Perfeccionada
ES1108057Y (es) Cascanueces